Vaxxinity (Vaxxinity) Interest Expense : $-0.70 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vaxxinity's interest expense for the three months ended in Dec. 2023 was $ -0.18 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.70 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vaxxinity's Operating Income for the three months ended in Dec. 2023 was $ -11.65 Mil. Vaxxinity's Interest Expense for the three months ended in Dec. 2023 was $ -0.18 Mil. Vaxxinity did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vaxxinity Interest Expense Historical Data

The historical data trend for Vaxxinity's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity Interest Expense Chart

Vaxxinity Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.44

-1.18

-0.84

-0.51

-0.70

Vaxxinity Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial											-0.25	-0.19	-0.15	-0.18	-0.18

Vaxxinity Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70 Mil.

Vaxxinity (OTCPK:VAXX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vaxxinity's Interest Expense for the three months ended in Dec. 2023 was $-0.18 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-11.65 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $13.26 Mil.

Vaxxinity's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Vaxxinity did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Vaxxinity (Vaxxinity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Odyssey Way, Merritt Island, FL, USA, 32953

Website

https://www.vaxxinity.com

Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.

Executives

Sumita Ray	officer: Chief Legal Officer, Secretary	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp	10 percent owner	P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade	director	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano	director	209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese	director, officer: Executive Chairman	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu	director, 10 percent owner, officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc	10 percent owner	25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss	10 percent owner	126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile	officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig	director	625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui	director	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292